PHAR - שולי רווח נקי ממכירות Pharming Group

The monopoly position of Pharming Group N.V. (PHAR) and the patent protection of orphan drugs guarantee stable demand. The sales margin ratio confirms this resilience, stabilizing at 6.20. The business foundation relies on leadership in the therapy of hereditary angioedema, while financial security is maintained through the balance between revenues from Ruconest and the costs of developing new enzyme preparations.
פילוחי נתונים אנליטיים מרוכזים עבור Pharming Corp (PHAR)

A conservative investor assesses the final business efficiency through the net profit margin, which reflects the amount of capital remaining after covering all operating and tax expenses. The steady growth of this metric for Pharming Group N.V. (PHAR) confirms high profitability in an undersaturated orphan drug market, where the expansion of the patient base in the US and Europe ensures long-term yield potential.